EOS® System Shown to offer Most Accurate Lower Limb Images with Lowest Radiation Dose in New Study
EOS® System Shown to offer Most Accurate Lower Limb Images
with Lowest Radiation Dose in New Study
Research Presented at Pediatric Orthopaedic Society of North America Meeting
PARIS--(BUSINESS WIRE)-- EOS imaging (NYSE Euronext, FR0011191766 - EOSI), the pioneer in orthopaedic 2D/3D imaging, today announced that new research shows the EOS® System offers more accurate lower limb imaging with significantly lower radiation exposure as compared to computed radiography (CR) and CT scan. The study was presented at the Pediatric Orthopaedic Society of North America (POSNA) Annual Meeting in Toronto, Canada, held May 1-4.
The study, titled "EOS Low-dose Biplanar Radiography: The New Gold Standard in Radiographic Assessment of Lower Limb Lengths?" was presented by orthopaedic surgeon Unni G. Narayanan, MD, of The Hospital for Sick Children in Toronto. It evaluated imaging of a phantom limb in a standardized position with three different modalities (CR, scanogram CT1, EOS in slow and fast speed) and compared measurement accuracy as well as radiation dose.
Researchers concluded that using EOS at a faster speed is more accurate than conventional CT and CR for the assessment of bone length and offers a much lower radiation exposure. Their results showed that mean absolute difference between the measurement and the true length of the femur was significantly lower with the EOS system (3.6mm; -0.8%) compared to CR (42.2mm; +8.8%) and scanogram CT (6.3mm; -1.3%). The mean radiation was also significantly lower for EOS-fast (0.68mrad) vs. CR (29.01mrad) and scanogram CT scans (3.74 mrad).
Marie Meynadier, CEO of EOS imaging, said, "This research continues to confirm that EOS offers both the most accurate weight-bearing orthopedic scans as well as the least amount of radiation exposure, eliminating the need to compromise scan quality or monitoring frequency in order to limit dose. We hope the research discussed at POSNA will serve as a model for pediatric centers across the world as they work to provide the highest quality orthopaedic care."
The EOS imaging system is the first and only full body, low dose 3D imaging technology available for orthopaedic care, developed to support the ALARA (As Low As Reasonably Achievable) principle of radiation dose management. For more information, please visit www.eos-imaging.com.
About EOS imaging:
EOS imaging designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). Backed by an installed base of over 60 sites and more than 350,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2012 the Group employed 63 people including an R&D team of 23 engineers, and posted 2012 consolidated revenue of €9.42 million. The Group is based in Paris and holds a United States subsidiary in Cambridge (Massachusetts) and offices in Montreal (Canada) and Germany.
For further information, please visit our website at www.eos-imaging.com.
EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 - Ticker: EOSI
Next update: half year 2013 revenues: July 17 after market close
1 CT scanograms are low dose 2D exams obtained using a CT scout view
Tel.: +33 (0)1 55 25 61 24
The Ruth Group (US)
Press Relations - Lisa Cook
Financial communication and investor relations
Sophie Boulila / Pierre Laurent
Tel.: +33 (0)1 44 71 94 91
ALIZE RP (Europe)
Tel: +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59
KEYWORDS: United States Europe North America France New York
The article EOS® System Shown to offer Most Accurate Lower Limb Images with Lowest Radiation Dose in New Study originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.